SlideShare ist ein Scribd-Unternehmen logo
1 von 24
Downloaden Sie, um offline zu lesen
Best approach to newly 
diagnosed multiple myeloma 
Elisabet Manasanch M.D., M.H.Sc. 
Assistant Professor, Department of Lymphoma/Myeloma 
Division of Cancer Medicine
Disclosures 
Nothing to disclose
Overview 
Outline 
Fit patients 
Unfit patients 
High risk multiple myeloma
Overview 
103,826 new cases 
72,453 deaths 
worldwide 
Incidence rate 
3-5/100,000 
Kihyun Kim et al. Clinical profiles of multiple myeloma in Asia – An Asian Myeloma Network Study. 2014. AJH. 
JH Lee et al. Multiple myeloma in Korea: past, present, and future perspectives. 2010. Int J Hematol. 
Blacks 
Age 70 years 
Incidence rate 
0.5-3/100,000 
Age 62 years
Overview 
Plasma cell malignancy – molecular heterogeneity 
Natural history progression from MGUS/SMM 
Evidence of end-organ damage 
GROUPS Associated translocations 
7 -> MF t(14;16) and t(14;20) 
6 -> CD-2 
CCND1/CCND3 
t(11;14) and t(6;14) activating 
Cyclin D 1 and Cyclin D3 
5 -> CD-1 
CCND1/CCND3 
t(11;14) and t(6;14) activating 
Cyclin D 1 and Cyclin D3 
4 -> HY Hyperdiploidy 
3 -> MS t(4;14), activation of FGFR3 and 
MMSET 
2 -> LB 
Low Bone 
Underexpression of DKK1 
1 -> PR 
PRoliferation 
Increased proliferation index 
Zhan et al. The molecular classification of multiple myeloma. Blood. 2006 / Lohr et al. Widespread genetic heterogeneity in multiple myeloma: 
Implications for targeted therapy. Cancer Cell. 2014.
Treatment History 
Dex VAD Thal+Dex CTD VD PAD Rd VTD RVD CRd 
Melphalan/ 
prednisone 
High-dose therapy with 
autologous stem cell 
HD dexamethasone 
VAD 
HD melphalan 
Autologous BM 
transplants 
support 
Lenalidomide 
Thalidomide 
Bortezomib 
Carfilzomib 
Pomalidomide 
Elotuzumab 
Daratumumab 
100 
80 
60 
40 
20 
0 
Sarcolysine 
1958 1962 1983-86 1996 1999 2003 2006 2012 
Patients with ≥ VGPR (%) 
S Kumar et al. Cancer Treatment Reviews 2010; Korde et al. ASH 2013.
Overview 
DIAGNOSTIC APPROACH 
Blood CBC with differential 
Complete chemistries 
LDH 
Serum quantitative immunoglobulins 
SPEP/IFE 
Serum β2-M and albumin 
Serum free light chain assay 
Urine 24 hour UPEP/IFE 
Pathology/Molecular Bone marrow biopsy (core and aspirate – unilateral) 
Metaphase cytogenetics 
FISH 
BM aspirate flow cytometry 
Gene expression profiling* 
Imaging Skeletal survey 
MRI/PETCT 
RA Kyle and SV Rajkumar. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009. Manasanch 
et al. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site 
and anticoagulation method. Leukemia and Lymphoma. 2014. In press.
Overview 
Outline 
Fit patients 
Unfit patients 
High risk multiple myeloma
Fit patients 
Absence of comorbidities, even if advanced age 
IFM 2005/01 GIMEMA HOVON-GMMG PETHEMA/GEM 
Harousseau 
VD vs VAD 
(n= 240 vs 242) 
JCO 2010 
Cavo 
VTD vs TD 
(n=241 vs 239) 
Blood 2012 
Sonneveld 
PAD vs VAD 
(n=417 vs 416) 
JCO 2012 
Rosinol 
VTD vs VBCMP/VBAD+V 
vs TD 
(n=130 vs 129 vs 127) 
Blood 2012 
Results post-ASCT 
CR 
(nCR+sCR) 
40% vs 18.4% 73.1% vs 60.9% 31% vs 15% 46% vs 38% vs 24% 
PFS (months) 36 vs 29.7 (S) NR vs 32 35 vs 28 (S) 56.2 vs 35.5 vs 28.2 (S) 
OS (months) 
Not reached (32 
months follow up) 
90% vs 88% at 3 
years 
Not reached (66 
months follow up) 
74% vs 70% vs 65% (4 
years) (NS) 
Most patients are treated with ASCT 
Phase III trials with bortezomib induction regimens
Combinations novel agents 
Phase II studies with small numbers of patients 
VRD 
CyBorD 
Richardson et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed mutiple 
myeloma. Blood. 2010. / Reeder et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed 
Multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009.
Combinations novel agents 
Randomized phase II study EVOLUTION (140 patients) 
8 x 3 week cycles initial therapy followed by 6-week cycles of bortezomib maintenance 
Small numbers of patients 
PFS at one year: 86 vs 83 vs 93 vs 100 (%) 
OS at one year: 94% vs 100% in all other arms 
S Kumar et al. Randomized, multicenter, phase 2 study(EVOLUTION). Blood. 2012
CRd in newly diagnosed MM 
Jakubowiak et al 
(Phase I/II, n = 53) 
Korde et al 
(Phase II, n = 45) 
Combination 
therapy 
CRd (Phase II Cfz 20/36 mg/m2) 
8 cycles 
CRd (Cfz 20/36 mg/m2) 
8 cycles 
Extended 
dosing 
CRd (Cfz every other week) 16 cycles, off-protocol 
Ln at last tolerated dose d1-21 
after 16 cycles 
Ln 10 mg d1-21, 
24 cycles 
Transplant ≥PR stem cell collection, HDM optional Stem cell collection 
Jakubowiak et al 
(Phase I/II, n = 53) 
Korde et al 
(Phase II, n = 45) 
ORR 
62% nCR/CR, 81% VGPR, 98% PR after 12 
cycles 
51% CR/nCR, all MRD 
negative (without ASCT) 
PFS 92% (at 24 months) 97% (at 12 months) 
A Jakubowiak et al. A phase ½ study of carfilzomib in combination with lenalidomide and low-dose dexamethasone 
as a frontline treatment for multiple myeloma. Blood. 2012 / N Korde et al. Phase II Clinical and Correlative Study of 
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates 
of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients. ASH abstract 538. 2013.
New agents in NDMM 
RANDOMIZED PHASE 3 STUDIES 
1.- IFM/DFCI: RVD with upfront or delayed autologous stem cell 
transplant 
2.- RVD vs CRd 
EARLY PHASE TRIALS 
1.- Carfilzomib, cyclophosphamide, dexamethasone 
2.- Carfilzomib, bendamustine, dexamethasone 
3.- Ixazomib, lenalidomide, dexamethasone 
4.- Ixazomib, cyclophosphamide, dexamethasone 
5.- RVD+ panabinostat 
6.- Cyclophosphamide, lenalidomide, dexamethasone
Overview 
Outline 
Fit patients 
Unfit patients 
High risk multiple myeloma
Velcade as initial treatment in newly diagnosed 
myeloma not eligible for transplant 
Randomized, international, phase III trial of VMP vs MP in 682 previously untreated patients 
with symptomatic MM who were not candidates for HDT-ASCT due to age (≥65 yrs) or 
co-morbid conditions 
VMP 
Cycles 1–4 
Bortezomib 1.3 mg/m2 IV: d 1,4,8,11,22,25,29,32 
Melphalan 9 mg/m2 and prednisone 60 mg/m2: 
d 1–4 
Cycles 5–9 
Bortezomib 1.3 mg/m2 IV: d 1,8,22,29 
Melphalan 9 mg/m2 and prednisone 60 mg/m2: 
d 1–4 
MP 
Cycles 1–9 
Melphalan 9 mg/m2 and prednisone 60 mg/m2: 
d 1–4 
R 
A 
N 
D 
O 
M 
I 
Z 
E 
9 x 6-week cycles (54 weeks) in both arms 
• Primary end 
point: TTP 
• Secondary end 
points: CR rate, 
ORR, time to 
response 
J San Miguel et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEJM. 2008
VISTA trial 
Time to progression Overall survival 
VMP: 24.0 months 
MP: 16.6 months 
P < .000001 
100 
80 
60 
40 
20 
0 
VMP 
MP 
Time (months) 
Median follow-up: 25.9 months 
3-year OS: 
VMP: 72% 
MP: 59% 
P = .0032 
VMP 
MP 
Time (months) 
0 3 6 9 12 15 18 21 24 27 
100 
80 
60 
40 
20 
0 
0 4 8 12 16 20 24 28 32 36 40 
682 patients 
RR: 71% VMP versus 35% MP 
Rate of CR: 30% VMP versus 4% MP 
J San Miguel et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEJM. 2008
HD vs LD lenalidomide. ECOG E4A03 
Four 28-day cycles 
1-yr OS 2-yr OS 
HD/lenalidomide 87% 75% 
LD/lenallidomide 96% 87% 
Transplant-eligible 
patients can 
proceed to SCT 
Continue therapy until 
disease progression 
Lenalidomide + High-Dose Dexamethasone (RD)a 
Len: 25 mg/day, days 1-21 
Dex: 40 mg/day, days 1-4, 9-12, 17-20 
(n = 223) 
Lenalidomide + Low-Dose Dexamethasone (Rd) 
Len: 25 mg/day, days 1-21 
Dex: 40 mg/day, days 1, 8, 15, 22 
(n = 222) 
Rajkumar et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as 
initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010.
Mateos MV et al. Proc ASH 2013;Abstract 403.
FIRST trial 
Progression Free Survival 
Overall Survival 
T. Facon et al. ASH 2013. Abstract 2.
Overview 
Outline 
Fit patients 
Unfit patients 
High risk multiple myeloma
High risk MM 
Genomic abnormalities 
FISH 
- del 17p 
- t(14:16) 
- t(14:20) 
GEP 
- High risk signature 
Laboratory abnormalities 
Renal failure 
Circulating plasma cells 
Increased LDH or B2M 
Moreau et al. Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) 
and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous 
Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death. JCO. 2014
High risk MM 
* Bortezomib containing regimens as initial treatment 
* Use of bortezomib consolidation/maintenance 
* Use of ASCT as consolidation 
* Explore tandem ASCT 
* Enroll in clinical trials if this is a possibility 
AK Nooka et al. Consolidation and maintenance therapy with lenalidomide, 
bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014.
Conclusions 
* Fit patients: 
*3 drug combination as initial therapy. 
*Stem cell collection and evaluation for ASCT. 
* Unfit patients: 
*VMP (other MPR, MPT) 
*Rd continuous treatment 
* High risk patients: 
*Refer for clinical trials 
*Use bortezomib (proteasome inhibitors) in 
consolidation/maintenance 
*Evaluate for ASCT/tandem ASCT
MDACC Myeloma Center 
Dr. Robert Orlowski 
Dr. Jatin Shah 
Dr. Donna Weber 
Dr. Sheeba Thomas 
Dr. Michael Wang 
Dr. Parmar 
Dr. Qazilbash 
Dr. Shah 
Dr. Bashir 
Stem Cell Transplant Department 
Support staff, nurses, coordinators 
Patients

Weitere ähnliche Inhalte

Was ist angesagt?

Approach to Autoimmune Hemolytic Anemia
Approach to Autoimmune Hemolytic AnemiaApproach to Autoimmune Hemolytic Anemia
Approach to Autoimmune Hemolytic AnemiaGayathri Nair
 
DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMSDIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMSNatalia Curto García
 
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev KumarAplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev KumarDr. Sookun Rajeev Kumar
 
Ppt Presentation For Pac 5110
Ppt Presentation For Pac 5110Ppt Presentation For Pac 5110
Ppt Presentation For Pac 5110pjaffey
 
MICROANGIOPATHIC HEMOLYTIC ANEMIA
MICROANGIOPATHIC HEMOLYTIC ANEMIAMICROANGIOPATHIC HEMOLYTIC ANEMIA
MICROANGIOPATHIC HEMOLYTIC ANEMIAbrijendra72u
 
Management of Multiple myeloma
Management of Multiple myelomaManagement of Multiple myeloma
Management of Multiple myelomaorthoprinciples
 
Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)Ahmed Makboul
 
approach to the diagnosis of anemia
approach to the diagnosis of anemiaapproach to the diagnosis of anemia
approach to the diagnosis of anemiaderosaMSKCC
 
Paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuriaParoxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuriaJoselle Balasa
 
Bleeding in liver disease - Wendon
Bleeding in liver disease - WendonBleeding in liver disease - Wendon
Bleeding in liver disease - Wendonintensivecaresociety
 
Polycythemia vera jak2
Polycythemia vera jak2Polycythemia vera jak2
Polycythemia vera jak2abhishek3096
 
Approach to Hemolytic Anemia
Approach to Hemolytic AnemiaApproach to Hemolytic Anemia
Approach to Hemolytic AnemiaAbdullah Ansari
 
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphomaDiffuse large B-cell lymphoma
Diffuse large B-cell lymphomamt53y8
 
Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Ahmed Makboul
 
acute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun Haldiaacute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun HaldiaDr Arun Haldia
 

Was ist angesagt? (20)

Approach to Autoimmune Hemolytic Anemia
Approach to Autoimmune Hemolytic AnemiaApproach to Autoimmune Hemolytic Anemia
Approach to Autoimmune Hemolytic Anemia
 
DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMSDIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
 
Acute leukemia
Acute leukemiaAcute leukemia
Acute leukemia
 
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev KumarAplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
 
Ppt Presentation For Pac 5110
Ppt Presentation For Pac 5110Ppt Presentation For Pac 5110
Ppt Presentation For Pac 5110
 
MICROANGIOPATHIC HEMOLYTIC ANEMIA
MICROANGIOPATHIC HEMOLYTIC ANEMIAMICROANGIOPATHIC HEMOLYTIC ANEMIA
MICROANGIOPATHIC HEMOLYTIC ANEMIA
 
Management of Multiple myeloma
Management of Multiple myelomaManagement of Multiple myeloma
Management of Multiple myeloma
 
Luspatercept
Luspatercept Luspatercept
Luspatercept
 
Thrombophilias
ThrombophiliasThrombophilias
Thrombophilias
 
Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)
 
approach to the diagnosis of anemia
approach to the diagnosis of anemiaapproach to the diagnosis of anemia
approach to the diagnosis of anemia
 
Paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuriaParoxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria
 
Bleeding in liver disease - Wendon
Bleeding in liver disease - WendonBleeding in liver disease - Wendon
Bleeding in liver disease - Wendon
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Polycythemia vera jak2
Polycythemia vera jak2Polycythemia vera jak2
Polycythemia vera jak2
 
Approach to Hemolytic Anemia
Approach to Hemolytic AnemiaApproach to Hemolytic Anemia
Approach to Hemolytic Anemia
 
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphomaDiffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
 
Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)
 
Autoimmune hemolytic anemia
Autoimmune hemolytic anemiaAutoimmune hemolytic anemia
Autoimmune hemolytic anemia
 
acute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun Haldiaacute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun Haldia
 

Andere mochten auch

Changing Landscape of Treatment for Multiple Myeloma
Changing Landscape of Treatment for Multiple MyelomaChanging Landscape of Treatment for Multiple Myeloma
Changing Landscape of Treatment for Multiple Myelomaspa718
 
Role of Flow Cytometric Immunophenotyping in Plasma Cell Dyscrasias
Role of Flow Cytometric Immunophenotyping in Plasma Cell DyscrasiasRole of Flow Cytometric Immunophenotyping in Plasma Cell Dyscrasias
Role of Flow Cytometric Immunophenotyping in Plasma Cell DyscrasiasApollo Hospitals
 
Management of multiple myeloma
Management of multiple myelomaManagement of multiple myeloma
Management of multiple myelomaDR Saqib Shah
 
Molecular pathology of lymphoma by dr ramesh
Molecular pathology of  lymphoma by dr ramesh Molecular pathology of  lymphoma by dr ramesh
Molecular pathology of lymphoma by dr ramesh Ramesh Purohit
 
CONTRAST INDUCED NEPHROPATHY
CONTRAST INDUCED NEPHROPATHYCONTRAST INDUCED NEPHROPATHY
CONTRAST INDUCED NEPHROPATHYfareedresidency
 
Linking t rna localization with activation
Linking t rna localization with activationLinking t rna localization with activation
Linking t rna localization with activationJoy Maria Mitchell
 
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
Multiple   Myeloma Modified ,  Dr  Gamal  Abdul  HamidMultiple   Myeloma Modified ,  Dr  Gamal  Abdul  Hamid
Multiple Myeloma Modified , Dr Gamal Abdul HamidGamal Abdul Hamid
 
MULTIPLE MYELOMA CELLS
MULTIPLE MYELOMA CELLSMULTIPLE MYELOMA CELLS
MULTIPLE MYELOMA CELLSRuchi
 
Genetics of attention deficit hyperactivity disorder (adhd)
Genetics of attention deficit hyperactivity disorder (adhd)Genetics of attention deficit hyperactivity disorder (adhd)
Genetics of attention deficit hyperactivity disorder (adhd)Joy Maria Mitchell
 

Andere mochten auch (16)

Changing Landscape of Treatment for Multiple Myeloma
Changing Landscape of Treatment for Multiple MyelomaChanging Landscape of Treatment for Multiple Myeloma
Changing Landscape of Treatment for Multiple Myeloma
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Update on plasma cell myeloma
Update on plasma cell myelomaUpdate on plasma cell myeloma
Update on plasma cell myeloma
 
1997 dergee certificate
1997 dergee certificate1997 dergee certificate
1997 dergee certificate
 
Role of Flow Cytometric Immunophenotyping in Plasma Cell Dyscrasias
Role of Flow Cytometric Immunophenotyping in Plasma Cell DyscrasiasRole of Flow Cytometric Immunophenotyping in Plasma Cell Dyscrasias
Role of Flow Cytometric Immunophenotyping in Plasma Cell Dyscrasias
 
Management of multiple myeloma
Management of multiple myelomaManagement of multiple myeloma
Management of multiple myeloma
 
Contrast Media
Contrast MediaContrast Media
Contrast Media
 
Molecular pathology of lymphoma by dr ramesh
Molecular pathology of  lymphoma by dr ramesh Molecular pathology of  lymphoma by dr ramesh
Molecular pathology of lymphoma by dr ramesh
 
CONTRAST INDUCED NEPHROPATHY
CONTRAST INDUCED NEPHROPATHYCONTRAST INDUCED NEPHROPATHY
CONTRAST INDUCED NEPHROPATHY
 
Linking t rna localization with activation
Linking t rna localization with activationLinking t rna localization with activation
Linking t rna localization with activation
 
Acute Lymphoblastic Lymphoma
Acute Lymphoblastic LymphomaAcute Lymphoblastic Lymphoma
Acute Lymphoblastic Lymphoma
 
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
Multiple   Myeloma Modified ,  Dr  Gamal  Abdul  HamidMultiple   Myeloma Modified ,  Dr  Gamal  Abdul  Hamid
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
 
MULTIPLE MYELOMA CELLS
MULTIPLE MYELOMA CELLSMULTIPLE MYELOMA CELLS
MULTIPLE MYELOMA CELLS
 
Genetics of attention deficit hyperactivity disorder (adhd)
Genetics of attention deficit hyperactivity disorder (adhd)Genetics of attention deficit hyperactivity disorder (adhd)
Genetics of attention deficit hyperactivity disorder (adhd)
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
PFGE
PFGEPFGE
PFGE
 

Ähnlich wie Newly Diagnosed Myeloma

Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Howard Friedman
 
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Mohamed Abdulla
 
Ovarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the SceneOvarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the SceneMohamed Abdulla
 
Malignant melanoma Standard of Care and Future Perspectives
Malignant melanoma Standard of Care and Future PerspectivesMalignant melanoma Standard of Care and Future Perspectives
Malignant melanoma Standard of Care and Future PerspectivesIrinaAlexandra12
 
METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017Mohamed Abdulla
 
smoldering myeloma
smoldering myelomasmoldering myeloma
smoldering myelomaspa718
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storyMohamed Abdulla
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Lethal midline granuloma treatment approach
Lethal midline granuloma treatment approachLethal midline granuloma treatment approach
Lethal midline granuloma treatment approachDr.Kaushik Sutradhar
 
Mantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicMantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicspa718
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myelomaspa718
 
Relapse Myeloma
Relapse MyelomaRelapse Myeloma
Relapse Myelomaspa718
 
Dr. maryalice stetler stevenson lymphoma mrd
Dr. maryalice stetler stevenson   lymphoma mrdDr. maryalice stetler stevenson   lymphoma mrd
Dr. maryalice stetler stevenson lymphoma mrdHitham Esam
 
Unmet need in multiple myeloma
Unmet need in multiple myelomaUnmet need in multiple myeloma
Unmet need in multiple myelomaPLMMedical
 
Orlowski mm rel_ref_celgene
Orlowski mm rel_ref_celgeneOrlowski mm rel_ref_celgene
Orlowski mm rel_ref_celgenespa718
 
PROSTATE CA222.pptx
PROSTATE CA222.pptxPROSTATE CA222.pptx
PROSTATE CA222.pptxLaithLutfi1
 
smoldering myeloma
smoldering myelomasmoldering myeloma
smoldering myelomaspa718
 

Ähnlich wie Newly Diagnosed Myeloma (20)

Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
 
Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...
Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...
Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...
 
Temozolomide As A Radiosensitizer Clinical Experience At Kmio
Temozolomide As A Radiosensitizer Clinical Experience At KmioTemozolomide As A Radiosensitizer Clinical Experience At Kmio
Temozolomide As A Radiosensitizer Clinical Experience At Kmio
 
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
 
Ovarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the SceneOvarian Cancer; What is Behind the Scene
Ovarian Cancer; What is Behind the Scene
 
Malignant melanoma Standard of Care and Future Perspectives
Malignant melanoma Standard of Care and Future PerspectivesMalignant melanoma Standard of Care and Future Perspectives
Malignant melanoma Standard of Care and Future Perspectives
 
Kyaw thura zaw
Kyaw thura zawKyaw thura zaw
Kyaw thura zaw
 
METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017
 
smoldering myeloma
smoldering myelomasmoldering myeloma
smoldering myeloma
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the story
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Lethal midline granuloma treatment approach
Lethal midline granuloma treatment approachLethal midline granuloma treatment approach
Lethal midline granuloma treatment approach
 
Mantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicMantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinic
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myeloma
 
Relapse Myeloma
Relapse MyelomaRelapse Myeloma
Relapse Myeloma
 
Dr. maryalice stetler stevenson lymphoma mrd
Dr. maryalice stetler stevenson   lymphoma mrdDr. maryalice stetler stevenson   lymphoma mrd
Dr. maryalice stetler stevenson lymphoma mrd
 
Unmet need in multiple myeloma
Unmet need in multiple myelomaUnmet need in multiple myeloma
Unmet need in multiple myeloma
 
Orlowski mm rel_ref_celgene
Orlowski mm rel_ref_celgeneOrlowski mm rel_ref_celgene
Orlowski mm rel_ref_celgene
 
PROSTATE CA222.pptx
PROSTATE CA222.pptxPROSTATE CA222.pptx
PROSTATE CA222.pptx
 
smoldering myeloma
smoldering myelomasmoldering myeloma
smoldering myeloma
 

Mehr von spa718

1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotaispa718
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery spa718
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancerspa718
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancerspa718
 
Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerspa718
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancerspa718
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancerspa718
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancerspa718
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancerspa718
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancerspa718
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancerspa718
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancerspa718
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015spa718
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancerspa718
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHDspa718
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myelomaspa718
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapyspa718
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapyspa718
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Updatespa718
 
Allogeneic HSCT in Elderly
Allogeneic HSCT in ElderlyAllogeneic HSCT in Elderly
Allogeneic HSCT in Elderlyspa718
 

Mehr von spa718 (20)

1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancer
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancer
 
Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancer
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancer
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancer
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancer
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancer
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancer
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancer
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancer
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHD
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myeloma
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapy
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapy
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Update
 
Allogeneic HSCT in Elderly
Allogeneic HSCT in ElderlyAllogeneic HSCT in Elderly
Allogeneic HSCT in Elderly
 

Kürzlich hochgeladen

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 

Kürzlich hochgeladen (20)

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 

Newly Diagnosed Myeloma

  • 1. Best approach to newly diagnosed multiple myeloma Elisabet Manasanch M.D., M.H.Sc. Assistant Professor, Department of Lymphoma/Myeloma Division of Cancer Medicine
  • 3. Overview Outline Fit patients Unfit patients High risk multiple myeloma
  • 4. Overview 103,826 new cases 72,453 deaths worldwide Incidence rate 3-5/100,000 Kihyun Kim et al. Clinical profiles of multiple myeloma in Asia – An Asian Myeloma Network Study. 2014. AJH. JH Lee et al. Multiple myeloma in Korea: past, present, and future perspectives. 2010. Int J Hematol. Blacks Age 70 years Incidence rate 0.5-3/100,000 Age 62 years
  • 5. Overview Plasma cell malignancy – molecular heterogeneity Natural history progression from MGUS/SMM Evidence of end-organ damage GROUPS Associated translocations 7 -> MF t(14;16) and t(14;20) 6 -> CD-2 CCND1/CCND3 t(11;14) and t(6;14) activating Cyclin D 1 and Cyclin D3 5 -> CD-1 CCND1/CCND3 t(11;14) and t(6;14) activating Cyclin D 1 and Cyclin D3 4 -> HY Hyperdiploidy 3 -> MS t(4;14), activation of FGFR3 and MMSET 2 -> LB Low Bone Underexpression of DKK1 1 -> PR PRoliferation Increased proliferation index Zhan et al. The molecular classification of multiple myeloma. Blood. 2006 / Lohr et al. Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell. 2014.
  • 6. Treatment History Dex VAD Thal+Dex CTD VD PAD Rd VTD RVD CRd Melphalan/ prednisone High-dose therapy with autologous stem cell HD dexamethasone VAD HD melphalan Autologous BM transplants support Lenalidomide Thalidomide Bortezomib Carfilzomib Pomalidomide Elotuzumab Daratumumab 100 80 60 40 20 0 Sarcolysine 1958 1962 1983-86 1996 1999 2003 2006 2012 Patients with ≥ VGPR (%) S Kumar et al. Cancer Treatment Reviews 2010; Korde et al. ASH 2013.
  • 7. Overview DIAGNOSTIC APPROACH Blood CBC with differential Complete chemistries LDH Serum quantitative immunoglobulins SPEP/IFE Serum β2-M and albumin Serum free light chain assay Urine 24 hour UPEP/IFE Pathology/Molecular Bone marrow biopsy (core and aspirate – unilateral) Metaphase cytogenetics FISH BM aspirate flow cytometry Gene expression profiling* Imaging Skeletal survey MRI/PETCT RA Kyle and SV Rajkumar. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009. Manasanch et al. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia and Lymphoma. 2014. In press.
  • 8. Overview Outline Fit patients Unfit patients High risk multiple myeloma
  • 9. Fit patients Absence of comorbidities, even if advanced age IFM 2005/01 GIMEMA HOVON-GMMG PETHEMA/GEM Harousseau VD vs VAD (n= 240 vs 242) JCO 2010 Cavo VTD vs TD (n=241 vs 239) Blood 2012 Sonneveld PAD vs VAD (n=417 vs 416) JCO 2012 Rosinol VTD vs VBCMP/VBAD+V vs TD (n=130 vs 129 vs 127) Blood 2012 Results post-ASCT CR (nCR+sCR) 40% vs 18.4% 73.1% vs 60.9% 31% vs 15% 46% vs 38% vs 24% PFS (months) 36 vs 29.7 (S) NR vs 32 35 vs 28 (S) 56.2 vs 35.5 vs 28.2 (S) OS (months) Not reached (32 months follow up) 90% vs 88% at 3 years Not reached (66 months follow up) 74% vs 70% vs 65% (4 years) (NS) Most patients are treated with ASCT Phase III trials with bortezomib induction regimens
  • 10. Combinations novel agents Phase II studies with small numbers of patients VRD CyBorD Richardson et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed mutiple myeloma. Blood. 2010. / Reeder et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed Multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009.
  • 11. Combinations novel agents Randomized phase II study EVOLUTION (140 patients) 8 x 3 week cycles initial therapy followed by 6-week cycles of bortezomib maintenance Small numbers of patients PFS at one year: 86 vs 83 vs 93 vs 100 (%) OS at one year: 94% vs 100% in all other arms S Kumar et al. Randomized, multicenter, phase 2 study(EVOLUTION). Blood. 2012
  • 12. CRd in newly diagnosed MM Jakubowiak et al (Phase I/II, n = 53) Korde et al (Phase II, n = 45) Combination therapy CRd (Phase II Cfz 20/36 mg/m2) 8 cycles CRd (Cfz 20/36 mg/m2) 8 cycles Extended dosing CRd (Cfz every other week) 16 cycles, off-protocol Ln at last tolerated dose d1-21 after 16 cycles Ln 10 mg d1-21, 24 cycles Transplant ≥PR stem cell collection, HDM optional Stem cell collection Jakubowiak et al (Phase I/II, n = 53) Korde et al (Phase II, n = 45) ORR 62% nCR/CR, 81% VGPR, 98% PR after 12 cycles 51% CR/nCR, all MRD negative (without ASCT) PFS 92% (at 24 months) 97% (at 12 months) A Jakubowiak et al. A phase ½ study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012 / N Korde et al. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients. ASH abstract 538. 2013.
  • 13. New agents in NDMM RANDOMIZED PHASE 3 STUDIES 1.- IFM/DFCI: RVD with upfront or delayed autologous stem cell transplant 2.- RVD vs CRd EARLY PHASE TRIALS 1.- Carfilzomib, cyclophosphamide, dexamethasone 2.- Carfilzomib, bendamustine, dexamethasone 3.- Ixazomib, lenalidomide, dexamethasone 4.- Ixazomib, cyclophosphamide, dexamethasone 5.- RVD+ panabinostat 6.- Cyclophosphamide, lenalidomide, dexamethasone
  • 14. Overview Outline Fit patients Unfit patients High risk multiple myeloma
  • 15. Velcade as initial treatment in newly diagnosed myeloma not eligible for transplant Randomized, international, phase III trial of VMP vs MP in 682 previously untreated patients with symptomatic MM who were not candidates for HDT-ASCT due to age (≥65 yrs) or co-morbid conditions VMP Cycles 1–4 Bortezomib 1.3 mg/m2 IV: d 1,4,8,11,22,25,29,32 Melphalan 9 mg/m2 and prednisone 60 mg/m2: d 1–4 Cycles 5–9 Bortezomib 1.3 mg/m2 IV: d 1,8,22,29 Melphalan 9 mg/m2 and prednisone 60 mg/m2: d 1–4 MP Cycles 1–9 Melphalan 9 mg/m2 and prednisone 60 mg/m2: d 1–4 R A N D O M I Z E 9 x 6-week cycles (54 weeks) in both arms • Primary end point: TTP • Secondary end points: CR rate, ORR, time to response J San Miguel et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEJM. 2008
  • 16. VISTA trial Time to progression Overall survival VMP: 24.0 months MP: 16.6 months P < .000001 100 80 60 40 20 0 VMP MP Time (months) Median follow-up: 25.9 months 3-year OS: VMP: 72% MP: 59% P = .0032 VMP MP Time (months) 0 3 6 9 12 15 18 21 24 27 100 80 60 40 20 0 0 4 8 12 16 20 24 28 32 36 40 682 patients RR: 71% VMP versus 35% MP Rate of CR: 30% VMP versus 4% MP J San Miguel et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEJM. 2008
  • 17. HD vs LD lenalidomide. ECOG E4A03 Four 28-day cycles 1-yr OS 2-yr OS HD/lenalidomide 87% 75% LD/lenallidomide 96% 87% Transplant-eligible patients can proceed to SCT Continue therapy until disease progression Lenalidomide + High-Dose Dexamethasone (RD)a Len: 25 mg/day, days 1-21 Dex: 40 mg/day, days 1-4, 9-12, 17-20 (n = 223) Lenalidomide + Low-Dose Dexamethasone (Rd) Len: 25 mg/day, days 1-21 Dex: 40 mg/day, days 1, 8, 15, 22 (n = 222) Rajkumar et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010.
  • 18. Mateos MV et al. Proc ASH 2013;Abstract 403.
  • 19. FIRST trial Progression Free Survival Overall Survival T. Facon et al. ASH 2013. Abstract 2.
  • 20. Overview Outline Fit patients Unfit patients High risk multiple myeloma
  • 21. High risk MM Genomic abnormalities FISH - del 17p - t(14:16) - t(14:20) GEP - High risk signature Laboratory abnormalities Renal failure Circulating plasma cells Increased LDH or B2M Moreau et al. Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death. JCO. 2014
  • 22. High risk MM * Bortezomib containing regimens as initial treatment * Use of bortezomib consolidation/maintenance * Use of ASCT as consolidation * Explore tandem ASCT * Enroll in clinical trials if this is a possibility AK Nooka et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014.
  • 23. Conclusions * Fit patients: *3 drug combination as initial therapy. *Stem cell collection and evaluation for ASCT. * Unfit patients: *VMP (other MPR, MPT) *Rd continuous treatment * High risk patients: *Refer for clinical trials *Use bortezomib (proteasome inhibitors) in consolidation/maintenance *Evaluate for ASCT/tandem ASCT
  • 24. MDACC Myeloma Center Dr. Robert Orlowski Dr. Jatin Shah Dr. Donna Weber Dr. Sheeba Thomas Dr. Michael Wang Dr. Parmar Dr. Qazilbash Dr. Shah Dr. Bashir Stem Cell Transplant Department Support staff, nurses, coordinators Patients

Hinweis der Redaktion

  1. Reeder: Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m2 orally on days 1, 8, 15 and 22 and dexamethasone 40 mg orally on days 1–4, 9–12 and 17–20 on a 28-day cycle for four cycles. All patients undergoing stem cell harvest Richardson: Abstract This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3 mg/m2 (days 1, 4, 8, 11), lenalidomide 15 to 25 mg (days 1-14), and dexamethasone 40 or 20 mg (days 1, 2, 4, 5, 8, 9, 11, 12). Responding patients proceeded to maintenance or transplantation. Phase 2 dosing was determined to be bortezomib 1.3 mg/m2, lenalidomide 25 mg, and dexamethasone 20 mg. Most common toxicities included sensory neuropathy (80%) and fatigue (64%), with only 27%/2% and 32%/3% grade 2/3, respectively. In addition, 32% reported neuropathic pain (11%/3%, grade 2/3). Grade 3/4 hematologic toxicities included lymphopenia (14%), neutropenia (9%), and thrombocytopenia (6%). Thrombosis was rare (6% overall), and no treatment-related mortality was observed. Rate of partial response was 100% in both the phase 2 population and overall, with 74% and 67% each achieving very good partial response or better. Twenty-eight patients (42%) proceeded to undergo transplantation. With median follow-up of 21 months, estimated 18-month progression-free and overall survival for the combination treatment with/without transplantation were 75% and 97%, respectively. Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105. had a successful collection. Twenty-three patients underwent stem cell transplantation (SCT) and are evaluable through day 100 with CR/nCR documented in 70% and XVGPR in 74%. VRD:
  2. Bz 1.3 1,4,8,11 Dex 40 mg weekly Cyclophosphamide 500 mg/m2 days 1 and 8 and 15 in vdc-mod Vdcr len 15 mg 1-14 Vdr len 25 mg 1-14
  3. VMP Cycles 1–4 Bortezomib 1.3 mg/m2 IV: d 1,4,8,11,22,25,29,32 Melphalan 9 mg/m2 and prednisone 60 mg/m2: d 1–4 Cycles 5–9 Bortezomib 1.3 mg/m2 IV: d 1,8,22,29 Melphalan 9 mg/m2 and prednisone 60 mg/m2: d 1–4 MP Cycles 1–9 Melphalan 9 mg/m2 and prednisone 60 mg/m2: d 1–4
  4. This ECOG trial is well recognized for determining that dexamethasone dosing of 40 mg/day on a 4-days-on, 4-days-off schedule is too high. This randomized trial of lenalidomide and dexamethasone compared the then-standard dosing of dexamethasone to a once-weekly dosage of 40 mg and found that survival was significantly improved in the low-dose dexamethasone arm -- 1-year OS was 87% with len/high-dose dex vs 96% with len/low-dose dex. Objective: to assess if a reduced dose of dex decreases toxicity while maintaining efficacy Primary endpoint: ORR after first 4 cycles aBased on the superiority of the Rd regimen, the study was stopped at a median follow-up of 12.5 months and patients in the RD arm crossed over to Rd therapy.
  5. * Half of the patients start with VMP and half with Rd. Treatment duration: 74 weeks